Investigational Gel Studied For Patients with Common, Precancerous Skin Lesions

ST. LOUIS -- Most of us may think AK is the postal abbreviation for the state of Alaska, but many farmers, construction workers, commercial fishermen, park rangers, lifeguards, sailors, golfers and at least two U.S. presidents know it stands for something else as well.

They know AK can stand for actinic keratosis, a common, pre-cancerous skin disease caused primarily by overexposure to the sun. Other risk factors include fair skin, light-colored hair and eyes, and genetic disorders. AKs especially are common in people whose occupations or hobbies result in repeated exposure to high intensity sunlight over many years.

Scott Fosko, M.D.

"While the majority of actinic keratoses do not progress to cancer, a significant number can, which is why finding an effective treatment with minimal side effects is critical," said Scott Fosko, M.D., of Saint Louis University, who is conducting a clinical trial involving an investigational gel to treat AK lesions.

The American Academy of Dermatology estimates that 60 percent of predisposed people older than 40 have at least one lesion. Both President George W. Bush and former President Bill Clinton has lesions removed.

"Older individuals are more likely to develop lesions, but we're seeing increasing numbers of younger adults at high risk of developing AK," said Fosko, a SLUCare physician and chairman of the department of dermatology at Saint Louis University School of Medicine.

Fosko is the primary investigator on a study to evaluate a new topical get to treat AK lesions, which appear as red, scaly bumps on areas such as the face, backs of the hands and arms. When the bumps become painful, Fosko said it usually is a sign that cancer is developing in them.

"Current treatment options include freezing the lesions and scraping them off or using a topical cream to treat wider areas," he said. "The creams available, however, often cause irritation and inflammation."

The investigational gel Fosko and his colleagues are evaluating may reduce such side effects.

Researchers currently are enrolling AK patients for the multi-center medication trial. Participants must be 18 or older and have at least five discrete lesions on their foreheads. Study medication and office visits will be provided at no cost to the patient.

For more information about this study, please call SLUCare at (314) 577-6087. SLUCare is the physician practice of Saint Louis University School of Medicine.

Editor's Note: To arrange an interview with Dr. Fosko, please contact Joe Muehlenkamp in Health Sciences Center media relations at (314) 977-8015.

[ Return to Top of Page ]